Special features of the psycho-emotional state of comorbid patients in therapist’s practice: what is important to take into consideration in their curation tactics

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Psycho-emotional disorders such as depression and anxiety disorders are important modifiable risk factors for the development and complications of many chronic non-communicable diseases. A special feature of such comorbidity is the significant negative impact of psychoemotional disorders at the motivation and adherence of patients to a healthy lifestyle and various variants of therapy. The actuality of screening and correction of psycho-emotional disorders in the practice of general practitioners is based, on the one hand, due to their high incidence in patients with chronic non-communicable diseases, deterioration of life quality and an increase in adverse outcomes, and, on the other hand, due to insufficient awareness of the possibilities of correcting the psycho-emotional state of patients with comorbidity. Therapy for psychoemotional disorders includes both drug and non-drug methods, however, the efficacy of such treatment in relation to the clinical course and prognosis in patients with different comorbidity options is not the same. Current review presents the most common variants of comorbidity of psycho-emotional disorders and somatic diseases in therapeutic practice.

Full Text

Restricted Access

About the authors

Veronika N. Shishkova

National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Healthcare of Russia; A.I. Yevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia

Author for correspondence.
Email: veronika-1306@mail.ru
ORCID iD: 0000-0002-1042-4275

MD, leading researcher, head of the Department of the prevention of cognitive and psychoemotional disorder; associate professor of the Department of therapy and preventive medicine

Russian Federation, Moscow; Moscow

References

  1. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392(10159): 1789–858. https://dx.doi.org/10.1016/S0140-6736(19)31047-5.15.
  2. Drapkina O.M., Kontsevaya A.V., Kalinina A.M. et al. 2022 prevention of chronic non-communicable diseases in of the Russian Federation. National guidelines. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2022; 21(4): 5–232 (In Russ.). https://dx.doi.org/10.15829/1728-8800-2022-3235. EDN: DNBVAT.
  3. Drapkina O.M., Shishkova V.N., Kotova M.B. Psychoemotional risk factors for non-communicable diseases in outpatient practice. guidelines for internists. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2022; 21(10): 97–117 (In Russ.). https://dx.doi.org/10.15829/1728-8800-2022-3438. EDN: SAGMPE.
  4. Shishkova V.N., Dranitsyna B.G., Drapkina O.M. Algorithms for the management of patients with anxiety in the internist’s practice. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2023; 22(2): 63–69 (In Russ.). https://dx.doi.org/10.15829/1728-8800-2023-3526. EDN: NKQFOC.
  5. Tong A., Wang X., Li F. et al. Risk of depressive symptoms associated with impaired glucose metabolism, newly diagnosed diabetes, and previously diagnosed diabetes: A meta-analysis of prospective cohort studies. Acta Diabetol. 2016; 53(4): 589–98. https://dx.doi.org/10.1007/s00592-016-0845-1.
  6. Palmer S., Vecchio M., Craig J.C. et al. Prevalence of depression in chronic kidney disease: systematic review and meta-analysis of observational studies. Kidney Int. 2013; 84(1): 179–91. https://dx.doi.org/10.1038/ki.2013.77.
  7. Xiao T., Qiu H., Chen Y. et al. Prevalence of anxiety and depression symptoms and their associated factors in mild COPD patients from community settings, Shanghai, China: A cross-sectional study. BMC Psychiatry. 2018; 18(1): 89. https://dx.doi.org/10.1186/s12888-018-1671-5.
  8. Krebber A.M., Buffart L.M., Kleijn G. et al. Prevalence of depression in cancer patients: A meta-analysis of diagnostic interviews and self-report instruments. Psychooncology. 2014; 23(2): 121–30. https://dx.doi.org/10.1002/pon.3409.
  9. Read J.R., Sharpe L., Modini M. et al. Multimorbidity and depression: A systematic review and meta-analysis. J Affect Disord. 2017; 221: 36–46. https://dx.doi.org/10.1016/j.jad.2017.06.009.
  10. Ronaldson A., de la Torre J.A., Prina M. et al. Associations between physical multimorbidity patterns and common mental health disorders in middle-aged adults: A prospective analysis using data from the UK Biobank. Lancet Reg Health Eur. 2021; 8: 100149. https://dx.doi.org/10.1016/j.lanepe.2021.100149.
  11. Long D.J., Ouyang Y., Duan H. et al. Multiple factor analysis of depression and/or anxiety in patients with acute exacerbation chronic obstructive pulmonary. Int J Chron Obstruct Pulmon Dis. 2020; 15: 1449–64. https://dx.doi.org/10.2147/COPD.S245842.
  12. Wen-Tao D., Xue-Xiu C., Zun-Jiang C. et al. The relationship between hospitalization frequency of acute exacerbation of chronic obstructive pulmonary disease and anxiety and depression. Front Genet. 2022; 13: 817727. https://dx.doi.org/10.3389/fgene.2022.817727.
  13. Volpato E., Toniolio S., Pagnini F., Banfi P. The relationship between anxiety, depression and treatment adherence in chronic obstructive pulmonary disease: A systematic review. Int J Chron Obstruct Pulmon Dis. 2021; 16: 2001–21. https://dx.doi.org/10.2147/COPD.S313841.
  14. Stallberg B., Janson C., Larsson K. et al. Real-world retrospective cohort study ARCTIC shows burden of comorbidities in Swedish COPD versus non-COPD patients. NPJ Prim Care Respir Med. 2018; 28(1): 33. https://dx.doi.org/10.1038/s41533-018-0101-y.
  15. Zareifopoulos N., Bellou A., Spiropoulou A., Spiropoulos K. Prevalence, contribution to disease burden and management of comorbid depression and anxiety in chronic obstructive pulmonary disease: A narrative review. COPD. 2019; 16(5–6): 406–17. https://dx.doi.org/10.1080/15412555.2019.1679102.
  16. Peyrot M., Rubin R.R., Lauritzen T. et al. Psychosocial problems and barriers to improved diabetes management: Results of the cross-national diabetes attitudes, wishes and needs (DAWN) study. Diabetes Med. 2005;22(10): 1379–85. https://dx.doi.org/10.1111/j.1464-5491.2005.01644.x.
  17. Perrin N.E., Davies M.J., Robertson N. et al. The prevalence of diabetes-specific emotional distress in people with type 2 diabetes: A systematic review and meta-analysis. Diabetes Med. 2017; 34(11): 1508–20. https://dx.doi.org/10.1111/ dme.13448.
  18. Mezuk B., Eaton W.W., Albrecht S., Golden S.H. Depression and type 2 diabetes over the lifespan: A meta-analysis. Diabetes Care. 2008; 31(12): 2383–90. https://dx.doi.org/10.2337/dc08-0985.
  19. Barnard K.D., Skinner T.C., Peveler R. The prevalence of co-morbid depression in adults with type 1 diabetes: Systematic literature review. Diabetes Med. 2006; 23(4): 445–48. https://dx.doi.org/10.1111/j.1464-5491.2006.01814.x.
  20. Huang C.J., Hsieh H.M., Tu H.P. et al. Generalized anxiety disorder in type 2 diabetes mellitus: Prevalence and clinical characteristics. Braz J Psychiatry. 2020; 42(6): 621–29. https://dx.doi.org/10.1590/1516-4446-2019-0605.
  21. Deschenes S., Burns R.J., Schmitz N. Associations between diabetes, major depressive disorder and generalized anxiety disorder comorbidity, and disability: Findings from the 2012 Canadian Community Health Survey – Mental Health (CCHS-MH). Psychosom Res. 2015; 78(2): 137–42. https://dx.doi.org/10.1016/j.jpsychores.2014.11.023.
  22. Asbjornsdottir B., Vestgaard M., Do N.C. et al. Prevalence of anxiety and depression symptoms in pregnant women with type 2 diabetes and the impact on glycaemic control. Diabet Med. 2021; 38(3): e14506. https://dx.doi.org/10.1111/dme.14506.
  23. Van der Feltz-Cornelis C., Allen S.F., Holt R.I.G. et al. Treatment for comorbid depressive disorder or subthreshold depression in diabetes mellitus: Systematic review and meta-analysis. Brain Behav. 2021; 11(2): e01981. https://dx.doi.org/10.1002/brb3.1981.
  24. Winkley K., Upsher R., Stahl D. et al. Psychological interventions to improve self-management of type 1 and type 2 diabetes: A systematic review. Health Technol Assess. 2020; 24(28): 1–232. https://dx.doi.org/10.3310/hta24280.
  25. Palmer S., Vecchio M., Craig J.C. et al. Prevalence of depression in chronic kidney disease: systematic review and meta-analysis of observational studies. Kidney Int. 2013; 84(1): 179–91. https://dx.doi.org/10.1038/ki.2013.77.
  26. Stasiak C.E.S., Bazan K.S., Kuss R.S. et al. Prevalence of anxiety and depression and its comorbidities in patients with chronic kidney disease on hemodialysis and peritoneal dialysis. J Bras Nefrol. 2014; 36(3): 325–31. https://dx.doi.org/10.5935/0101-2800.20140047.
  27. Nagler E.V., Webster A.C., Vanholder R., Zoccali C. Antidepressants for depression in stage 3-5 chronic kidney disease: A systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP). Nephrol Dial Transplant. 2012; 27(10): 3736–45. https://dx.doi.org/10.1093/ndt/gfs295.
  28. Chilcot J., Farrington K. The case for selective withdrawal of antidepressants in patients with advanced kidney disease. J Am Soc Nephrol 2019; 30(7): 1339–40. https://dx.doi.org/10.1681/ASN.2019030308.
  29. Wasteson E. Mood disorders in patients with cancer. Lancet Oncol. 2011; 12(2): 114–15. https://dx.doi.org/10.1016/S1470-2045(11)70007-9.
  30. Krebber A.M.H., Buffart L.M., Kleijn G. et al. Prevalence of depression in cancer patients: Meta-analysis of diagnostic interviews and self-report instruments. Psychooncology. 2014; 23(2) :121–30. https://dx.doi.org/10.1002/pon.3409.
  31. Wang Y.H., Li J.Q., Shi J.F. et al. Depression and anxiety in relation to cancer incidence and mortality: A systematic review and meta-analysis of cohort studies. Mol Psychiatry. 2020; 25(7): 1487–99. https://dx.doi.org/10.1038/s41380-019-0595-x.
  32. Celano C.M., Millstein R.A., Bedoya C.A. et al. Association between anxiety and mortality in patients with coronary artery disease: A meta-analysis. Am Heart J. 2015; 170(6): 1105–15. https://dx.doi.org/10.1016/j.ahj.2015.09.013.
  33. Shishkova V.N., Ustarbekova D.B., Shishkov V.A. et al. Psycho-emotional disorders in chronic heart failure patients. Terapiya = Therapy. 2022; 8(1): 44–49 (In Russ.). https://dx.doi.org/10.18565/therapy.2022.1.44-49. EDN: JKEKXX.
  34. Vaccarino V., Badimon L., Bremner J.D. et al. Depression and coronary heart disease: 2018 position paper of the ESC working group on coronary pathophysiology and microcirculation. Eur Heart J. 2020; 41(17): 1687–96. https://dx.doi.org/10.1093/eurheartj/ehy913.
  35. Daskalopoulou M., George J., Walters K. et al. Depression as a risk factor for the initial presentation of twelve cardiac, cerebrovascular, and peripheral arterial diseases: Data linkage study of 1.9 million women and men. PLoS One. 2016; 11(4): e0153838. https://dx.doi.org/10.1371/journal.pone.0153838.
  36. Peters A., McEwen B.S. Stress habituation, body shape and cardiovascular mortality. Neurosci Biobehav Rev. 2015; 56: 139–50. https://dx.doi.org/10.1016/j.neubiorev.2015.07.001.
  37. Albus C., Waller C., Fritzsche K. et al. Significance of psychosocial factors in cardiology: Update 2018: Position paper of the German Cardiac Society. Clin Res Cardiol. 2019; 108(11): 1175–96. https://dx.doi.org/10.1007/s00392-019-01488-w.
  38. Smyth A. Physical activity and anger or emotional upset as triggers of acute myocardial infarction: The INTERHEART study. Circulation. 2016; 134(15): 1059–67. https://dx.doi.org/10.1161/CIRCULATIONAHA.116.023142.
  39. Evstifeeva S.E., Shalnova S.A., Makarova Yu.K. et al. Is the population level of anxiety and depression associated with mortality? Data from the ESSE-RF study. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2021; 20(5): 252–261 (In Russ.). https://dx.doi.org/10.15829/1728-8800-2021-3009. EDN: LCPZLS.
  40. Moise N., Khodneva Y., Jannat-Khah D.P. et al. Observational study of the differential impact of time-varying depressive symptoms on all-cause and cause-specific mortality by health status in community-dwelling adults: The REGARDS study. BMJ Open. 2018; 8(1): e017385. https://dx.doi.org/10.1136/bmjopen-2017-017385.
  41. Ye S., Muntner P., Shimbo D. et al. Behavioral mechanisms, elevated depressive symptoms, and the risk for myocardial infarction or death in individuals with coronary heart disease: The REGARDS (Reason for Geographic and Racial Differences in Stroke) study. J Am Coll Cardiol. 2013; 61(6): 622–30. https://dx.doi.org/10.1016/j.jacc.2012.09.058.
  42. Tully P.J., Cosh S.M., Baumeister H. The anxious heart in whose mind? A systematic review and meta-regression of factors associated with anxiety disorder diagnosis, treatment and morbidity risk in coronary heart disease. J Psychosom Res. 2014; 77(6): 439–48. https://dx.doi.org/10.1016/j.jpsychores.2014.10.001.
  43. Thompson D.R., Ski S.F. Psychosocial interventions in cardiovascular disease – what are they? Eur J Prev Cardiol. 2013; 20(6): 916–17. https://dx.doi.org/10.1177/2047487313494031.
  44. Pizzi C., Rutjes A.W., Costa G.M. et al. Meta-analysis of selective serotonin reuptake inhibitors in patients with depression and coronary heart disease. Am J Cardiol. 2011; 107(7): 972–79. https://dx.doi.org/10.1016/j.amjcard.2010.11.017.
  45. He W., Zhou Y., Ma J. et al. Effect of antidepressants on death in patients with heart failure: A systematic review and meta-analysis. Heart Fail Rev. 2020; 25(6): 919–26. https://dx.doi.org/10.1007/s10741-019-09850-w.
  46. Honkola J., Hookana E., Malinen S. et al. Psychotropic medications and the risk of sudden cardiac death during an acute coronary event. Eur Heart J. 2012; 33(6): 745–51. https://dx.doi.org/10.1093/eurheartj/ehr368.
  47. Shishkova V.N. Strategy for the management and prevention of psycho-emotional disorders in the GP’s practice. Meditsinskiy sovet = Medical Council. 2023; 17(6): 76–82 (In Russ.). https://dx.doi.org/10.21518/ms2023-077. EDN: ZUOVBB.
  48. Vein A.M., Artemenko A.R., Onkin V.Yu. et al. The effectiveness of grandaxin in the correction of psychovegetative disorders. Lecheniye nervnykh bolezney = Treatment of Nervous Diseases. 2001: 9–20 (In Russ.).
  49. Statsenko M.E., Govoruha O.A. Influence of grandaxin on indicators of quality of life and rate of rehabilitation of patients with heart failure after myocardial infarction. Yuzhno-Rossiyskiy meditsinskiy zhurnal = Southern Russian Medical Journal. 2003; (5–6): 13–21 (In Russ.). EDN: WQUWXL.
  50. Kuleshova E.V. The use of tofisopam (grandaxin) for the treatment of patients with coronary heart disease. Klinicheskaya farmakologiya i terapiya = Clinical Pharmacology and Therapy. 2000; 9(5): 53–55 (In Russ.).
  51. Osipenko M.F., Khramov Yu.L., Makarova T.A. et al. The role of grandaxin in the treatment of functional diseases of the gastrointestinal tract. Terapevticheskiy arkhiv = Therapeutic Archive. 2000; 72(10): 23–27 (In Russ.).
  52. Goldin B.G., Savitskaya I.V. Grandaxin in the treatment of anxiety disorders in patients with bronchial asthma. V mire lekarstv: klinicheskaya farmakologiya i farmakoterapiya = In the World of Medicines: Clinical Pharmacology and Pharmacotherapy. 1999; (3–4): 82–84 (In Russ.). EDN: YQBKXD.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies